B+
Bull case
30%
Probability
Target price
$26.00
Analysis reference price unavailable
Analysis 2026-05-05 · RankAlpha Sentiment Codex
NRIX
Nurix TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is that Nurix now has a clearer registrational path around bexobrutideg, with an ongoing pivotal Phase 2 study designed to support potential Accelerated Approval and a planned confirmatory Phase 3 start by mid-2026, while the balance sheet still showed $540.7 million at February 28, 2026 [#8-K-2026-04-08] [#10-Q-2026-04-08].
Posture
Defensive
Lead driver
Value
What changed
3 setup hits (3d) with net bullish as of 2026-10-24.
What can break
Execution risk around enrollment, data quality, and timing is significant for a company whose equity story is concentrated in bexobrutideg milestones and partner-program progress.
Momentum
79
Value
41
Sentiment
26
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $18.00 · Bull $26.00 · Bear $10.00Analysis 2026-05-05; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-05 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Bullish
Target $34.50
Why
Momentum79 · Δ7d +20.3
Value41 · Δ7d -0.1
Sentiment26 · Δ7d -1.8
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Confirming evidence
- • 3 setup hits (3d) with net bullish as of 2026-10-24.
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • Execution risk around enrollment, data quality, and timing is significant for a company whose equity story is concentrated in bexobrutideg milestones and partner-program progress.
- • Funding risk remains material beyond the next year: the 10-Q says existing cash should support operations for at least 12 months, but not completion of clinical trials through commercialization [#10-Q-2026-04-08].
- • The bear case is that revenue fell to $6.3 million from $18.5 million as Sanofi collaboration revenue stepped down, R&D rose to $84.1 million, and Nurix explicitly said existing cash is not sufficient to fund clinical development through commercialization, leaving future financing and execution risk material [#8-K-2026-04-08] [#10-Q-2026-04-08].
Catalyst clock
2026-06-30
Mid-2026 Phase 3 bexobrutideg trial start
Lead driver: Value · See fundamentals
Momentum
79
8% active weight
Current posture
7d trendImproving
Δ7d
+20.3
Δ21d
+12.7
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
26
45% active weight
Current posture
7d trendSoftening
Δ7d
-1.8
Δ21d
-13.7
Why this grade
Composite grade F. Momentum 79.1 / Value 40.6 / Sentiment 26.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-05. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-05-05 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-05-05 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$2.77B
Beta
1.96
Shares Out
109.25M
P/E (TTM) · Derived
-8.3
P/S (TTM)
21.18
P/FCF (TTM) · Derived
-8.36
Rev YoY
-79.5%
EPS YoY
+55.5%
Gross Margin
+53.1%
Op Margin
-982.4%
Net Debt
-$537.21M
Current Ratio
6.34
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data